

MedDrive is Prime Therapeutics' comprehensive suite of medical drug management solutions to help clients lower their rising specialty drug spend. It includes maximizing medical drug savings and increasing use of biosimilars, a growing drug category that creates a timely opportunity for savings.

Why biosimilars?

✓ SAFE +
EFFECTIVE

Biosimilars are as safe and effective as biologics¹

↑ 29
APPROVED

29 biosimilars are currently FDA-approved, with more in the pipeline²

↓ 15% TO
35% LESS

Biosimilars cost 15%–35% less than their biologic alternatives³

\$100
BILLION

Using biosimilars could reduce drug costs by \$100 billion over the next five years⁴

What makes MedDrive market leading?



FIRST-OF-ITS-KIND ALIGNED MEDICAL DRUG MANAGEMENT PROGRAM

- Harnesses the collective strength of Blue + Prime alignment on preferred drug lists to deliver fully transparent drug management solutions
- Integrates various parts of the health care ecosystem to support biosimilars
- Promotes biosimilars as a safe, effective, affordable treatment to key stakeholders



PROVEN SAVINGS

In the oncology class, one client shifted biosimilar use from below 25% market share to 80%–90%. This resulted in **several millions of dollars** in overall savings to the health plan.



MARKET-LEADING MEDICAL DRUG MANAGEMENT

- Best-in-class pharmaceutical manufacturer savings
- Integrated data analytics and insights
- Proactive consultation and clinical resources
- Comprehensive solutions for turnkey health plan implementation

1. Biosimilar Development, Review, and Approval, Oct 20, 2017. U.S. FDA.

Accessed at: <https://www.fda.gov/drugs/biosimilars/biosimilar-development-review-and-approval>

2. FDA-approved Biosimilar Products. <https://www.fda.gov/drugs/biosimilars/biosimilar-product-information>

3. FDA and FTC Announce New Efforts to Further Deter Anti-Competitive Business Practices, Support Competitive Market for Biological Products to Help Americans. Feb. 3, 2020. FDA News release. FDA.gov. Accessed at: <https://www.fda.gov/news-events/press-announcements/fda-and-ftc-announce-new-efforts-further-deter-anti-competitive-business-practices-support>

4. Biosimilars in the United States 2020-2024: Competition, Savings, and Sustainability. September 29, 2020. IQVIA Institute Report. Accessed at: <https://www.iqvia.com/insights/the-iqvia-institute/reports/biosimilars-in-the-united-states-2020-2024>

To learn more about MedDrive and the significant savings opportunities it offers, contact your Prime representative or visit Prime's newsroom at www.primetherapeutics.com